Pharmaceutical Technology-12-02-2012

Job Security - Annual Employment Survey Results Show Increased Confidence

As the battle against counterfeits gains momentum, PharmTech speaks to Mark Davison, CEO of Blue Sphere Health, and Craig Stobie, global life sciences sector manager at Domino Printing Sciences, about the challenges involved.

In addition to globalisation, high financial rewards and low penalties for counterfeiters are contributing to the rise in fake medicines.

A few years ago, drug criminals would put all their efforts into matching packaging and labeling, or manufacturing good-looking fake materials. Today, criminals are capable of much more.

To ensure the accuracy of scientific testing, protect the subjects to avoid data contamination.

PDA's strategic plan calls for maintaining valuable and effective relationships with global regulators.

The quest to build critical mass and broaden capabilities has been a key factor in deal-making.

GlaxoSmithKline recently developed a novel technology for the formulation of modified-release tablets. The authors describe the route from development to commercialization.

White House and Congress likely to struggle over funding for bio/pharmaceutical regulation.

Annual employment survey results show greater confidence in the pharma industry.

An interview with Eric M. Parker, Ph.D., Executive Director and Neuroscience Site Lead, Merck Research Laboratories, about the Merck BACE team's winning research.

Can postapproval FDA filings immunize pharma companies from patent lawsuits?

A look at the year's leaders in innovation strategy, including the top bio/pharmaceutical companies and award recipients from AAPS, PhRMA, and CPhI.

Adeline Siew PharmTech speaks to Lynne Byers and Brian Johnson about Rx-360's initiatives to protect patient safety.

A change in terminology could emphasize patient protection.

New product reviews for December 2012.

Q&A with Richard Shor, President of SaniSure.

Domestic companies are changing their business models in response to recent drug price cuts.

As 2012 comes to a close, Pfizer leads among Big Pharma companies for FDA approvals of new molecular entities and biologics.

Clean-in-place systems should be optimized during design and commissioning and after validation.